Cytogenetic effects in children treated with methylphenidate.

Area of Science:

• Pharmacology
• Genetics
• Pediatrics

Background:

• Methylphenidate (Ritalin) is widely prescribed for Attention Deficit/Hyperactivity Disorder (ADHD) in children.
• Concerns exist regarding the potential mutagenicity and carcinogenicity of methylphenidate.
• Limited data is available on the cytogenetic effects of methylphenidate in pediatric populations.

Purpose of the Study:

• To investigate whether therapeutic doses of methylphenidate induce cytogenetic abnormalities in children with ADHD.
• To assess the impact of methylphenidate on chromosome aberrations, sister chromatid exchanges, and micronuclei frequencies.

Main Methods:

• A study population of twelve pediatric patients treated with therapeutic methylphenidate doses.
• Analysis of peripheral blood lymphocytes for cytogenetic endpoints before and after three months of treatment.
• Evaluation of chromosome aberrations, sister chromatid exchanges, and micronuclei frequencies.

Main Results:

• Methylphenidate treatment led to significant increases in cytogenetic abnormalities.
• A 3-fold increase in chromosome aberrations was observed (P=0.000).
• A 4.3-fold increase in sister chromatid exchanges (P=0.000) and a 2.4-fold increase in micronuclei (P=0.000) were also found.

Conclusions:

• Therapeutic methylphenidate doses induce significant cytogenetic abnormalities in pediatric patients.
• The findings suggest a potential health risk associated with methylphenidate use.
• Further research is warranted to explore the long-term health effects, including cancer risk, linked to these genetic changes.